Different types of cancer cells express PD-1 ligands, such as programmed death-ligand 1 (PD-L1) and PD-L2, which bind to PD-1 and inhibit signaling pathways, leading to T-cell exhaustion and suppression of immune-mediated antitumor responses [11]. Here, PDCD1LG2 is linked to cancer.